The core uses a patent-pending, modified mRNA/miRNA-based method to reprogram somatic cells into induced pluripotent stem cells (iPSCs). This cutting-edge technology was developed by the co-directors of the core, Drs. Kogut and Bilousova (High-efficiency RNA-based reprogramming of human primary fibroblasts. Nature Communications. (2018). https://doi.org/10.1038/s41467-018-03190-3). It provides the following significant advantages over traditional cell reprogramming approaches such as lentiviral-, episomal-, and Sendai virus-based methods:
- ultra-high yield (up to 90%)
- cost effective
We provide up to 5 early passage iPSC clones per reprogrammed cell line (2 vials per clone)
Primary fibroblast lines provided by a customer, or isolated by the core from provided skin biopsies, are reprogrammed into iPSCs. Our protocol is approximately 18 days (iPSC colonies can be seen as early as day 13). If desired, a complete characterization profile can be provided post reprogramming.
|Fibroblast Isolation From Skin Biopsy
|iPSCs culturing and expansion
Renal cell reprogramming
The core personnel is skilled in developing primary renal epithelial cell (REC) lines from human urine specimens and reprogramming REC lines into iPSCs. Please contact us for more information.
Note: a copy of approved IRB protocol(s) must be provided by customers before reprogramming patient-derived cells